| Similar Articles |
|---|
 |
Pharmaceutical Executive
August 1, 2012
Debbie Warner |
Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.   |
Pharmaceutical Executive
February 1, 2012
Jill Wechsler |
Costs and Benefits of Health Reform Will expanded markets and accountable care organizations offset higher rebates, added fees, and closer scrutiny of marketing and prices? |
Commercial Investment Real Estate
Jul/Aug 2012
Andrew Dick |
Healthcare Headaches Various issues delay medical real estate construction. |
BusinessWeek
June 23, 2011
Drew Armstrong |
The Simplest Rx: Check on Your Patient Doctors and insurers cut costs by sharing information. |
Pharmaceutical Executive
September 1, 2013
Shantanu Agrawal |
Making Sense of the Sunshine Act: A New Era for Drug Promotion Now that the Sunshine Act's Open Payments spending disclosure program is live, the federal government's lead officer for compliance explains how the new web-based system will work and how US industry, providers, and patients will be better off by making their relationships fully transparent. |
Nursing Management
October 2011
Edna Cadmus |
Your role in redesigning healthcare We need to rethink how we provide care and to understand the interconnectedness and the structure of healthcare by looking at it as a whole vs. the sum of its parts. As leaders we need to view the evidence as we rethink healthcare together. |
Nursing Management
April 2011
Deborah E. Trautman |
Healthcare Reform: 1 Year Later A year after the Patient Protection and Affordable Care Act was signed into law, the nation remains divided. |
Pharmaceutical Executive
February 1, 2006
Jill Wechsler |
Washington Report: Cross-Agency Collaboration for Part D Medicare Part D gives CMS more clout over coverage, pricing, and even drug development. |
Managed Care
July 2007
Martin Sipkoff |
Hospitals Asked To Account For Errors on Their Watch Centers for Medicare & Medicaid Services and states may stop paying for specific hospital-acquired conditions. Will health plans follow suit? |
Pharmaceutical Executive
November 1, 2005
Rubinstein & Galardi |
Bustin' a CAP: The Competative Acquisition Program The new Competitive Acquisition Program for Medicare Part B drugs aims to align market forces with the distribution of drugs and biologics that doctors administer in their offices, but increasing bureaucracy is a major downside. |
Managed Care
May 2002
Frank Diamond |
Medicare+EvenMoreChoice: U.S. Encourages PPO Option The government offers financial incentives that include $100,000 in seed money, risk-sharing deals, and higher payment rates |
Managed Care
March 2006
Taylor & Eck |
It's Time for CMS to Release Physician Medicare Claim Information The Center for Medicare & Medicaid Services is a rich source of price and quality data. Isn't it about time it shared that data? |
The Motley Fool
September 23, 2009
Brian Orelli |
Witch Hunt, Round 2? Humana mails Medicare Advantage members about health-care reform, and not everyone approves. |
Pharmaceutical Executive
December 1, 2010
Ansis Helmanis |
A New Twist in the Cost Curve The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Is industry prepared to adapt or challenge? |
Managed Care
February 2006
Martin Sipkoff |
Don't Bet That Problems With Part D Are Over Medicare Part D enrollment snags could be just the start of political and regulatory headaches facing health plans and pharmacy benefit managers. |
Pharmaceutical Executive
August 1, 2011 |
Employers: Fighting Non-Adherence A Q and A with Andrew Webber, President and CEO of the National Business Coalition on Health |
